RxDoctor Payments Data

Emily Newlin

Family · Lafayette, INNPI 1265086565

Payments from drug & device makers

$3,939in general payments, 2019–2025

Across 178 payments — averaging $22.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • AbbVie$605
  • Sanofi$389
  • Takeda Pharmaceuticals U.S.A., Inc.$331
  • Madrigal Pharmaceuticals$206
  • Regeneron Healthcare Solutions, Inc.$148
  • plus $822 from 15 others

What the payments were for

  • Food & beverage$3,930100%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,939 in reported general payments places this provider in the 90th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$49,640
Medicare patients
342
Services billed
580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide15$22,116
Budesonide DrBudesonide24$13,341
Esomeprazole Magnesium59$2,518
CholestyramineCholestyramine (With Sugar)32$2,403
Pantoprazole Sodium189$2,034
Omeprazole154$1,774
Famotidine227$1,502
Ondansetron OdtOndansetron28$1,057
Ondansetron Hcl28$175
Atorvastatin Calcium18$158
Lisinopril15$57
Trazodone Hcl11$10

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$605$22,11615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,392 family providers in Indiana.

Other family in Lafayette

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →